CJA
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text (PDF)
Right arrow Submit a scholarly reply
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by FRIESEN, C. M.
Right arrow Articles by DILLINGHAM, M. F.
Right arrow Search for Related Content
PubMed
Right arrow Articles by FRIESEN, C. M.
Right arrow Articles by DILLINGHAM, M. F.

Canadian Journal of Anesthesia, Vol 26, 319-321, Copyright © 1979 by Canadian Anesthesiologists' Society

Successful Use of Dantrolene Sodium in Human Malignant Hyperthermia Syndrome: A Case Report

CLIFFORD M. FRIESEN M.D.1, JAY B. BRODSKY M.D.1, and MICHAEL F. DILLINGHAM M.D.1

1 Stanford University School of Medicine, Stanford, California 94305, U.S.A.

We present a case of malignant hyperthermia in which successful management included the intravenous use of dantrolene sodium. A subsequent operation under spinal anaesthesia with oral dantrolene prophylaxis did not lead to development of malignant hyperthermia. Since this syndrome is rare during regional anaesthesia, the role of prophylactic oral dantrolene in preventing the redevelopment of malignant hyperthermia in our patient is open to question.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1979 by the Canadian Anesthesiologists' Society.